# MOTS-c: Research Overview > MOTS-c: Research Overview — Definitive Peptides — A cited research overview of MOTS-c, a mitochondrial-derived peptide studied for AMPK-driven metabolic and exercise-mimetic effects. Mechanism, mouse and human association data, and open questions. **05 / RESEARCH PEPTIDE FUNDAMENTALS** A 16-amino-acid peptide encoded inside mitochondrial DNA, with a well-mapped cell and mouse mechanism and, so far, no human interventional trial data at all. ## The short version MOTS-c is unusual among peptides: it is not encoded by a gene in the cell nucleus like almost everything else in the body, but by a short stretch of DNA inside the mitochondria, the small structures that generate cellular energy. It is only 16 amino acids long, and researchers believe it acts as a signal the mitochondria send to the rest of the cell — and, under stress, all the way to the cell's nucleus — to adjust metabolism. MOTS-c is the newest and least-studied compound on this reference desk. Its mechanism is genuinely well characterized in cells and mice, including a 2024 discovery of its direct molecular binding partner. But there is no published human trial testing whether giving people MOTS-c does anything at all — the only human data are observational, measuring naturally circulating MOTS-c levels rather than testing an injected dose. ## What it is MOTS-c is a 16-amino-acid peptide (sequence MRWQEMGYIFYPRKLR) encoded by a short open reading frame inside the mitochondrial 12S ribosomal RNA gene (MT-RNR1) — meaning it comes from the mitochondrial genome itself, not the cell's nuclear DNA where most proteins are encoded. It belongs to a small family of "mitochondrial-derived peptides" discovered over the past two decades, and its sequence is highly conserved across mammals, suggesting an evolutionarily important function. ## How it works MOTS-c's best-characterized action is inhibition of the folate cycle and the cell's own purine-building machinery, which raises a signaling molecule called AICAR and activates AMP-activated protein kinase (AMPK) — a master metabolic switch that improves glucose uptake and insulin sensitivity, primarily in skeletal muscle. Under metabolic stress, MOTS-c has been shown to move from the mitochondrion into the cell nucleus, where it helps regulate gene expression, including antioxidant-defense genes, in an AMPK-dependent way [27]. A 2024 study went a step further and identified a direct molecular target: MOTS-c binds and activates an enzyme called casein kinase 2 (CK2), and this binding works differently in different tissues — activating CK2 in muscle while suppressing it in fat, which the study links to MOTS-c's effects on muscle glucose uptake and prevention of muscle wasting [23]. ## What the research shows *Direct molecular target identified.* A 2024 study established that MOTS-c directly binds and activates casein kinase 2 in cell-free systems, and that tissue-specific modulation of CK2 — activating it in muscle, suppressing it in fat — underlies MOTS-c's effects on muscle glucose uptake and its prevention of muscle atrophy in mice, including young, aged, high-fat-diet and immobilized animals [23]. *The strongest human data are observational.* A prospective, multicenter cohort of 94 chronic hemodialysis patients, followed for a median of 26.5 months, found that naturally circulating MOTS-c levels were independently associated with a combined risk of death and non-fatal cardiovascular events, and adding MOTS-c to a risk model improved its discriminative accuracy [24]. This is real human clinical-association evidence — but it measures a biomarker, not the effect of administering the peptide. *Consolidated mechanism review.* A comprehensive 2023 review synthesizes MOTS-c biology across its mitochondrial encoding, AMPK/folate-cycle mechanism, stress-induced nuclear translocation, exercise-inducibility, and proposed roles in metabolism, stress adaptation and aging, and serves as the field's standard orientation reference [25]. *Exercise-mimetic effects in mice.* Exercise induces the body's own MOTS-c production in muscle and blood, and giving mice exogenous MOTS-c significantly improved physical performance across young, middle-aged and old animals — including a significant increase in treadmill running capacity, grip strength and gait quality in aged mice — positioning MOTS-c as a research candidate for an "exercise mimetic" [26]. *Discovery of nuclear signaling.* Under metabolic stress, MOTS-c was shown to translocate from mitochondria to the nucleus and regulate nuclear gene expression, including antioxidant-response genes via the NRF2 pathway, in an AMPK-dependent manner — the first demonstration that a mitochondrial-encoded peptide can send this kind of retrograde signal to the nucleus [27]. ## Reported effects, cautions & safety MOTS-c is the one compound on this reference desk where the corpus behind this site turned up **no meaningful body of community-reported effects and no dedicated cited safety-caution literature** — a direct reflection of how new and thinly studied it still is outside cell and animal work. Rather than fill that gap with speculation, this section states plainly what the broader literature does establish as open questions. Every claim above about MOTS-c improving metabolism, muscle preservation, or physical performance comes from cell or animal studies, predominantly mice. There is no published human interventional trial, no established human pharmacokinetics, and no measured human half-life or dose-response — rodent dosing cannot be responsibly extrapolated to people. MOTS-c is not approved by the FDA for any use and is sold only as a research chemical, so product purity, identity and sterility vary by supplier and are not regulated as pharmaceuticals would be. It is also treated as a prohibited substance in elite sport by anti-doping authorities, and some of the human association research on MOTS-c has come from smaller or single-cohort studies awaiting independent replication. Genetic variation also appears to matter: a MOTS-c gene variant carried by some populations has been linked to different metabolic effects, a reminder that findings in one group may not generalize evenly. ## Where it fits in research peptide fundamentals MOTS-c is the frontier compound on this desk — the one whose cell-and-mouse mechanism is unusually well characterized, including a direct molecular target discovered as recently as 2024, but whose human evidence consists entirely of an observational biomarker study rather than any trial of the peptide itself. That combination sets it apart from every other compound here: even [CJC-1295](/cjc-1295) and [BPC-157](/bpc-157), which also lack approval, have at least a handful of controlled human dosing studies behind them. See the [comparison page](/compare) for how MOTS-c's evidence tier compares across all five. --- Definitive Peptides is an independent research desk that traces every claim on this site to a cited source — not a clinic, not a supplier, and never a substitute for a licensed clinician's judgment.